Projects

Juno Therapeutics Headquarters and R&D Facility, Washington

Juno Therapeutics, a biopharmaceutical company engaged in developing innovative cellular immunotherapy drugs for the treatment of cancer, inaugurated its new headquarters and research and development (R&D) facility in Washington, US, in September 2017.

Project Type
Headquarters and research centre
Location
Seattle, Washington, US
Construction Started
January 2016
Investment
$232m
Inaugurated
September 2017
Floor Area
90,000ft²
Designer
CollinsWoerman
Owner
Alexandria Real Estate Equities

Juno Therapeutics has inaugurated a new research and development (R&D) facility with an investment of $232m.

The biopharmaceutical company is engaged in developing innovative cellular immunotherapy drugs for the treatment of cancer.

Covering 90,000ft², the new headquarters is located in a 375,000ft² lab and office building situated at 400 Dexter Avenue North, South Lake Union, Seattle.

Juno filed an application with the US Securities and Exchange Commission to lease the top four floors of the 12-storey building for a period of seven years beginning February 2017. The agreement includes three five-year options, which allow Juno to lease three more floors covering an area of 71,000ft².

The company will pay a base rent of $48 per square foot for the first year and will increase it by up to 2.5% a year.

Opened in September, the facility will allow researchers and scientists to collaborate on the R&D of immunotherapy treatments and will contribute to the long-term growth of  the biotechnology sector in Seattle.

Design and features of Juno Therapeutics’ new headquarters

The state-of-the-art biotech facility features research laboratories and office spaces to accommodate the company’s researchers, scientists, technical professionals, and administrative staff, who were previously located at three separate sites.

The building features 269,700ft² of laboratory and office space, a 13,800ft² retail area on the first floor, and a 128,000ft² carpark with 457 below-grade parking spaces. The third level is dedicated to a complete mechanical room to serve the needs of the occupants.

The building is constructed with steel frames, while the exterior comprises glass and masonry structures. Open space is provided towards south and rooftop deck.

Construction of Juno’s headquarters and R&D facility

Design work on the on Juno Therapeutics’ headquarters and R&D facility was completed in February 2015. A ground-breaking ceremony was held in June 2015 and construction was commenced in January 2016.

Salvaged site materials were used in the construction, helping to gain Leadership in Energy and Environmental Design (LEED) Gold environmental standard certification.

Contractors involved

The life sciences building at 400 Dexter was designed by architect CollinsWoerman and is owned by Alexandria Real Estate Equities.

BNBuilders was contacted by Alexandria Real Estate Equities to carry out the construction. Costigan Integrated provided design and construction management, owner’s representation, and cost estimation services under a subcontract from Alexandria Real Estate Equities.

PSF Mechanical was selected as the design-build mechanical contractor for the building.

Juno Therapeutics awarded a contract worth $43m to Skanska in October 2016 to complete the 155,000ft², seven-floor tenant improvement works at the building.

Other contractors involved with the project are Weisman Design Group, Hart Crowser, and KPFF Consulting Engineers.

Marketing commentary on Juno Therapeutics

Established in 2013, Juno Therapeutics aims to develop new product candidates using its cell-based platform to treat a wide range of cancers and other human diseases.

With more than 500 employees, the company develops cancer immunotherapies using chimeric antigen receptor (CAR) and high-affinity T cell receptor (TCR) technologies to genetically engineer patient’s own immune cells to treat cancer.

The company is currently developing multiple cell-based product candidates for the treatment of B-cell malignancies, solid tumours, and myeloma.

Related Projects